Background-Vaccines against norovirus, the leading cause of acute gastroenteritis, should protect against medically significant illness and reduce transmission.
37.5%; P = .074) were less frequent. Vaccination also reduced the modified Vesikari score from 7.3 to 4.5 (P = .002). Difficulties encountered were low norovirus disease rate, and inability to define illness by quantitative RT-PCR or further antibody rise in vaccinees due to high vaccineinduced titers. By day 10, 11 of 49 (22.4%) vaccinees were shedding virus compared with 17 of 47 (36.2%) placebo recipients (P = .179).
Conclusions-Bivalent norovirus VLP vaccine reduced norovirus-related vomiting and/or diarrhea; field efficacy studies are planned.
Clinical Trials Registration-NCT01609257.
Keywords norovirus; vaccine; challenge; acute gastroenteritis Noroviruses are the leading cause of epidemic and sporadic outbreaks of gastroenteritis worldwide [1] , and the most important cause of foodborne illness [2] . They cause up to 71 000 hospitalizations and 800 deaths annually [3] . Since rotavirus vaccine introduction, noroviruses have become the leading cause of medically attended acute gastroenteritis in US children, associated with nearly 1 million healthcare visits annually [4] .
Norovirus is a genus within the Caliciviridae family, classified into at least 6 genogroups (GI-GVI) and further into 29 genotypes based on the major viral capsid protein (VP1), including the 3 genogroups that infect humans (GI, GII, and GIV) [5] . Vaccine development is a challenge because of the diversity and low cross-reactivity between genogroups, which is further hampered by the inability to culture the virus and the lack of small animal models that mimic human disease [6] .
Experimental norovirus vaccines composed of virus-like particles (VLPs) expressing VP1 are generally well tolerated and immunogenic when administered either orally [7, 8] , intramuscularly [9] , or intranasally [10] . A norovirus GI.1 monovalent VLP vaccine protected against illness and infection following challenge with homologous GI.1 Norwalk virus [11] , prompting development of a bivalent GI.1/GII.4 VLP vaccine [12] , as these 2 genogroups account for the majority of norovirus outbreaks [13] [14] [15] [16] [17] . The GII.4 component is a consensus VLP derived from 3 naturally occurring GII.4 variants that induced broadly reactive antibody responses in animal studies and may induce a multivalent response against different genotypes [12] .
METHODS

Study Design
We conducted a randomized, double-blind, placebo-controlled trial at 5 sites in the United States from May 2012 to July 2013. The study protocol was approved by the institutional review board of each site, registered at ClinicalTrials.gov (NCT01609257), and performed according to current Good Clinical Practices and Declaration of Helsinki guidelines. Coprimary objectives were to (1) compare the rates of norovirus acute gastroenteritis (AGE) following challenge with a norovirus GII.4 strain in vaccine and placebo recipients, and (2) evaluate the safety and tolerability of 2 doses of the investigational vaccine.
Subjects
Eligible subjects were healthy adults 18-50 years of age of either sex, able to provide written informed consent, and available for the study follow-up visits. Exclusion criteria included working in healthcare, food services, or childcare; being pregnant or nursing; close contact with persons at risk of complications from norovirus infection; abnormal results of physical and common laboratory evaluations; positive test results for human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or bacterial and parasitic stool infections. To ensure susceptibility to the challenge virus, only subjects with a functional FUT2 gene determined by the presence of salivary histo-blood group antigens (HBGAs) were included, after screening for enzyme-linked immunosorbent assay (ELISA) antibodies to the P domain of the challenge strain, with a titer cutoff of ≤1:1600 for eligibility [18] .
Vaccine
The vaccine formulation contained 100 µg of norovirus VLPs (50 µg each of GI.1 and GII.4 VLPs), produced in a baculovirus expression system and adjuvanted with 50 µg of 3-Odesacyl-4′-monophosphoryl lipid A adjuvant (3-O-desacyl-4′-monophosphoryl lipid A, GlaxoSmithKline) and 0.5 mg of aluminum hydroxide (Brenntag Biosector A/S, Denmark) per dose, administered in 0.5 mL by intramuscular injection. The GI.1 component was a Norwalk virus VLP [11] , the GII.4 component was designed by aligning 3 GII.4 capsid protein sequences and determining the "consensus" amino acid residues at each position as previously described [12] . Placebo was sterile saline (0.5 mL).
Norovirus Challenge Strain and Challenge Procedure
The Eligible participants were randomized (1:1) to receive study vaccine or placebo, stratified by clinical site, with 2 doses injected in the deltoid 4 weeks apart. Solicited adverse events (AEs) were collected for 7 days and unsolicited AEs for 28 days after each study dose. Serious adverse events (SAEs) were collected for 1 year after last study dose. Serum samples for immunogenicity analyses were collected before administration of each dose and 4 weeks after the second study dose, and serum samples for laboratory safety analyses were collected 14 days after each immunization.
At least 28 days after the second study dose, eligible participants were admitted to an inpatient challenge facility. Eighty percent were challenged by day 42, with a range up to day 196. They were given a clear liquid meal 5 hours before challenge, and could have clear liquids until 90 minutes before challenge when all intake was stopped. Approximately 2 minutes after drinking 60 mL of 2% sodium bicarbonate solution to buffer stomach acids, subjects drank the challenge virus in 80 mL of sterile water, followed 5 minutes later by another 60 mL of 2% sodium bicarbonate solution. They then refrained from eating and drinking for at least 90 minutes.
After challenge, subjects remained in the inpatient facility for a minimum of 96 hours and until they were free of vomiting or diarrhea for ≥18 hours. They were evaluated twice daily by an investigator, and the severity of each prespecified sign and symptom was graded by the subject on a scale of 0 (no change in health) to 3 (incapacitating or unable to perform usual activities). A prespecified modification of the Vesikari scoring scale was also applied, based on the number of episodes and duration of vomiting and diarrhea, the presence of fever, and the need for intravenous rehydration [11] . All stool and emesis specimens were collected, graded, and weighed. Aliquots from 1 representative stool sample per subject were collected on days 1-4, 10, and 30 postchallenge. The stools were then processed and stored for testing for norovirus shedding. Additional serum samples taken before and 30 days after challenge were tested for anti-GII.4 norovirus antibodies. All subjects had access to oral rehydration solution. Before discharge, abnormal clinical laboratory analyses were repeated, and followed to resolution or stability.
Illness Definitions
Acute gastroenteritis was predefined as diarrhea (≥3 loose or liquid stools or >400-600 g of loose or liquid stools produced in any 24-hour period) or vomiting (≥2 vomiting episodes in any 24-hour period), or 1 vomiting episode plus any loose or liquid stool in any 24-hour period, or 1 vomiting episode plus at least 2 of the following 5 events: nausea, oral temperature ≥37.6°C, abdominal cramps or pains, abdominal gurgling or bloating, or myalgia in any 24-hour period. Norovirus GII.4 infection was to be confirmed by seroresponse (≥4-fold rise in anti-GII.4 norovirus P particle antibody titer from prechallenge to postchallenge) or fecal virus excretion detected by quantitative RT-PCR (qRT-PCR) on any day postchallenge. Norovirus disease met both criteria.
Laboratory Assays
Monoclonal antibody-based saliva binding assays using antibodies specific for salivary Le b , Le y , and H type 1 HBGAs (Covance Inc) were used to select secretor-positive subjects [19, 20] . Serum antibodies to the GII.4 P particle were measured for screening and determination of infection [18, 21] , and seroresponses to the vaccine were measured using a total serum antibody ELISA [11] .
Whole stool specimens were tested for the presence of the norovirus challenge strain (GII.4 Farmington Hills) with a strain-specific TaqMan-based qRT-PCR assay targeting the P2 region of the major capsid gene, with viral load determined against a standard curve of RNA transcripts.
Statistical Analysis
A sample size of 60 per group was selected to have approximately 45 subjects per group challenged, which would provide ≥95% power in comparing AGE illness rates between groups assuming a 50% illness rates in placebo recipients ( [17] and unpublished data) and an efficacy of 70%. Illness rates and infection rates were compared between groups by Fisher exact test. Start and stop times of AGE were determined by a committee review of coded listings of individual subject clinical signs and symptoms. Severity of illness was based on a previously reported modification of the Vesikari scale, with a maximum possible score of 17 [11] . Severity and duration were compared between groups by the Wilcoxon rank-sum test. Time to onset was compared between groups using a log-rank test and was limited to those who were ill and infected. Viral shedding was assessed by analysis of variance of the logarithmic transformation of the area under the curve defined by viral load by day postchallenge.
Geometric mean titers (GMTs) and geometric mean fold rises of antibodies were compared between groups by Wilcoxon rank-sum test, and seroresponse rates (percentages of subjects with ≥4-fold rises) were compared between groups by Fisher exact test. All reported P values are 2-sided. All data analyses and statistical computations were conducted with SAS software (version 9.3).
RESULTS
Study Population and Demographics
Of the 132 secretor-positive volunteers who were enrolled and randomized, 127 (63 vaccine and 64 placebo) received both study injections; 23 of these subjects did not participate in the challenge stage. Subsequently, 109 (56 vaccine and 53 placebo) subjects were challenged with oral norovirus GII.4, and 98 were eligible for the per-protocol analysis as identified by a blinded review by the clinical evaluation committee. Reasons for all attritions are shown in Table 1 . Results in per-protocol and modified intent-to-treat populations were similar, so only per-protocol evaluations are presented except for lab abnormalities.
Demographic data for vaccine and placebo groups were similar for both the vaccine stage and challenge stage, with a slight predominance of male sex and black race ( Table 2) .
Safety and Tolerability
There were no SAEs reported throughout the study period (excluding severe acute gastroenteritis due to challenge virus). Injection site reactions, predominantly tenderness, were frequent in vaccinees (34/50 [68.0%]) compared with placebo recipients (21/48 [43.8%]), but were mainly mild to moderate, lasting <4 days ( Figure 1A ). Systemic reactions were reported by 21 of 50 (42.0%) vaccinees and 18 of 48 (37.5%) placebo recipients ( Figure 1B) . Fever was detected in 1 vaccinee (2.0%) and 2 placebo recipients (4.2%). Clinical laboratory abnormalities were infrequent and occurred in similar proportions in vaccine and placebo groups. During the vaccination stage, 10 laboratory abnormalities (5 in vaccinees and 5 in placebo recipients) in 6 subjects were considered clinically significant. Only 3 of these were considered to be possibly related to vaccination (all occurred in the same subject): grade 3 elevated direct and total bilirubin and grade 1 elevated alanine aminotransferase occurring at the day 14 follow-up after the second dose. All laboratory abnormalities returned to normal.
Vaccine Immunogenicity
The first immunization produced robust responses against GI.1 and GII.4 as measured 28 days after the immunization (Table 3) . Notably, the fold increases in ELISA GMTs after the first vaccination were greater for GI. 
Efficacy
After challenge, 57 of the 98 subjects were infected, as evidenced by detection of the challenge virus in fecal specimens: 27 of 50 (54.0%) vaccinees and 30 of 48 (62.5%) placebo recipients (Table 4) . Seroresponses (4-fold increase in immunoglobulin G P-particle titers) after challenge were detected in 26 of 30 (86.7%) placebo recipients who shed virus, but in only 4 of 27 (14.8%) vaccinees who shed virus. Using the predefined definitions of norovirus gastroenteritis, based on the number of episodes and volume of diarrhea and vomitus as well as selected symptoms, the vaccine did not significantly reduce the incidence of protocol-defined illness, with 13 (26.0%) cases among vaccinees and 16 (33.3%) in placebo recipients (Table 4) . Vaccination appeared to reduce the incidence of acute norovirus gastroenteritis based on vomiting and diarrhea reported by the subjects (Table 4) : Severe vomiting or diarrhea was reported by 4 of 48 (8.3%) placebo recipients and 0 of 50 vaccinees (P = .054), moderate or severe vomiting or diarrhea by 9 of 48 (18.8%) placebo recipients and 3 of 50 (6.0%) vaccinees (P = .068), and vomiting or diarrhea of mild or greater severity by 18 of 48 (37.5%) placebo recipients and 10 of 50 (20.0%) vaccinees (P = .074).
To eliminate any bias in identification of norovirus in each group, we also compared the incidence of all reported illnesses regardless of meeting the criteria for norovirus infection ( Table 4) . The results were the same except for the comparison of vomiting or diarrhea of mild or greater severity, which was now significant (P = .028). Notably, all cases of moderate or greater vomiting or diarrhea were confirmed to be infected. Using the modified Vesikari scale as a global assessment, the severity of disease was reduced from 7.3 ± 2.0 in the placebo group to 4.5 ± 2.1 in the vaccine group in those who became ill and infected (P = .002). Neither the duration of norovirus illness nor the time to onset of norovirus illness was significantly different in vaccinees with breakthrough disease compared with placebo recipients.
The primary study endpoint required confirmation of norovirus infection by at least 1 of 2 different assays. Quantitative RT-PCR identified infection in both study groups, but at a rate that was somewhat lower than in previous challenge studies [11, 18] , and both symptomatic and asymptomatic infections were identified. One subject who self-reported mild illness did not become positive for infection by qRT-PCR until the outpatient phase of the study. As prechallenge antibody titers were high in vaccine recipients, apparently peaking at a higher level than that induced by the challenge, a 4-fold rise in GII.4 antibodies following norovirus challenge could only be demonstrated in placebo recipients; only 2 vaccinees vs 16 placebo recipients (88% reduction) had protocol-defined illness plus a 4-fold rise in GII.4 antibody in the per-protocol population (P < .001). Seven subjects (2 vaccinees and 5 placebo) met 1 of the protocol definitions of illness but were negative for norovirus infection by either the stool qRT-PCR or serological assay.
Fecal shedding of challenge virus (Figure 2 ) peaked on days 3-4 after challenge. The quantity of virus was higher in those who became ill compared with those who remained asymptomatic according to protocol definitions after infection (analysis of variance log [area under the curve]; P = .005), although both symptomatic and asymptomatic infected subjects shed virus over a wide range of values. One vaccine recipient was negative for viral shedding by qRT-PCR during the inpatient phase of the study, but positive for a 4-fold increase in antibody titer. The subject later became positive by qRT-PCR during the outpatient phase. Vaccinees appeared to clear virus more rapidly so that mean concentrations on day 4 and later were lower than those in placebo recipients. On day 10, 11 of 49 (22.4%) vaccinees were shedding virus compared with 17 of 47 (36.2%) placebo recipients (P = . 179).
DISCUSSION
In this first efficacy evaluation of a candidate bivalent VLP norovirus vaccine, the vaccine was found to be well-tolerated and immunogenic, and appeared to reduce acute gastroenteritis (vomiting and/or diarrhea) induced by challenge with GII.4 norovirus as reported by the subjects. Similarly, the vaccine reduced the severity of disease when evaluated using the modified Vesikari score, from 7.3 to 4.5 (P = .002).The vaccine was more protective against severe forms of acute gastroenteritis than against mild disease, consistent with other vaccines. The increasing efficacy against more severe disease is similar to what has previously been seen with rotavirus vaccines [22] . Part of the inability to demonstrate efficacy using the predefined criteria for gastroenteritis might reflect the fact that some subjects met the predefined criteria but did not self-report the presence of any vomiting or diarrhea. Furthermore, some subjects who met the predefined illness criteria were not confirmed to be norovirus-infected by either the qRT-PCR stool assay or the serological assay. This illustrates the complexity of conducting a challenge study and objectively measuring infection and illness. Vaccination offered several potentially beneficial effects for public health, including fewer subjects with symptomatic disease, and an observed decrease in viral shedding, both in terms of duration and quantity of virus shed.
Previously, the GI.1 component of the vaccine was shown to be efficacious against challenge with a GI.1 challenge strain, Norwalk virus, when administered by the nasal route [11] . In that study, vaccine reduced the incidence of Norwalk virus gastroenteritis by 47% (95% CI, 15%-67%), and reduced the severity of disease as assessed by the modified Vesikari score from 5.5 to 3.6 (P = .009) [11] . There are several important differences between the studies of monovalent vaccine and GI.1 challenge compared with the bivalent vaccine and GII.4 challenge reported here. These include (1) the route of immunization (intranasal vs intramuscular); (2) the challenge virus (homologous to vaccine vs heterovariant; the GII.4 challenge strain and the GII.4 antigen in the vaccine differed by 19 amino acids in the hypervariable domain of the norovirus capsid protein); (3) the definition of disease; and (4) the incidence of disease in the control group.
There are several issues in the epidemiology and immunology of norovirus that may be critical to vaccine development [23] . Genetic diversity of norovirus both between and within genogroups might present a major challenge. Therefore, the evaluated candidate vaccine is bivalent to extend protection to both GI.1 and GII.4 viruses. Furthermore, the GII.4 component was derived using a consensus sequence with the intent of providing multivalent protection; previous work has suggested that infection with Norwalk virus (GI.1) can induce antibody that can block binding of other GI viruses [25] . Guinea pigs immunized with the consensus GII.4 VLP used in the present study induced antibodies that recognized other GII. 4 VLPs from clinical samples representing 30 years of genetic drift [12] . Importantly, serum samples from other subjects who received the same bivalent vaccine have been found to have cross-blocking antibody to the GII.4 Sydney 2012 strain that emerged after vaccinations were completed (L. Lindesmith and R. Baric, personal communication). Additional studies will be required to determine the extent to which the candidate vaccine will provide multivalent protection against genetically drifted norovirus strains and genotypes not included in the vaccine. The optimization of illness definitions and diagnostic assays to attribute illness to norovirus will be important aspects of these future studies.
Remaining questions for the development of a safe and effective norovirus vaccine include immunogenicity and protection in different age groups, and the duration of protection that can be provided by vaccination. Mathematical modeling studies of community norovirus transmission suggest that protection from natural infection lasts 4.1-8.7 years [24] . Although duration of protection following vaccination remains to be determined, even shortlived protection could be beneficial for controlling symptoms and transmission in populations that are clustered in confined spaces, such as military personnel in barracks or cruise ship passengers, or in outbreak situations such as those which occur in nursing homes or hospitals.
There is increasing attention on norovirus-associated burden of illness and healthcare costs, with estimated hospitalization costs for pediatric norovirus infections of $3918 and norovirus-related emergency room visits at $435, with even higher costs in older adults [4] . A vaccine preventing moderate to severe disease may be expected to decrease hospitalizations and emergency room visits, and reduce associated healthcare costs, as seen with rotavirus vaccines. The vaccine used in the present trial may fulfill these criteria, but large field efficacy studies are needed to confirm the degree to which protection can be achieved against norovirus illness in the community, including vaccine efficacy studies in adults, children, and the elderly. Viral load in stools (as viral count per milligrams of stool) in vaccine and placebo subjects according to whether they were ill (per-protocol definition) over the 10 days of postchallenge with norovirus GII.4. 
